PRESS RELEASE published on 08/14/2024 at 14:00, 2 years 1 month ago Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update Xenetic Biosciences, Inc. reports financial results for Q2 2024, focusing on DNase-based oncology program in preclinical studies with data due before year end. Ended quarter with $7.3M cash Financial Results Xenetic Biosciences Cash Balance DNase-based Oncology Program Preclinical Studies
BRIEF published on 05/22/2024 at 23:05, 2 years 3 months ago Xenetic Biosciences, Inc. annonce une transition de direction Développement Clinique Oncologie Leadership Executif Biosciences Xénétiques James Parslow
BRIEF published on 05/22/2024 at 23:05, 2 years 3 months ago Xenetic Biosciences, Inc. Announces Executive Leadership Transition Xenetic Biosciences Oncology Clinical Development Executive Leadership James Parslow
PRESS RELEASE published on 05/22/2024 at 23:00, 2 years 3 months ago Xenetic Biosciences, Inc. Announces Executive Leadership Transition Xenetic Biosciences appoints James F. Parslow as interim CEO. The company focuses on innovative immune-oncology technologies for hard-to-treat cancers Xenetic Biosciences Clinical Development Pancreatic Carcinoma James Parslow Immune-oncology Technologies
BRIEF published on 05/10/2024 at 14:35, 2 years 4 months ago Xenetic Biosciences publie ses résultats financiers et ses progrès commerciaux pour le premier trimestre 2024 Résultats Financiers Biosciences Xénétiques Programme D'oncologie Thérapie Basée Sur La DNase Etudes Précliniques
BRIEF published on 05/10/2024 at 14:35, 2 years 4 months ago Xenetic Biosciences Reports Q1 2024 Financial Results and Business Progress Financial Results Xenetic Biosciences Oncology Program DNase-based Therapy Preclinical Studies
PRESS RELEASE published on 05/10/2024 at 14:30, 2 years 4 months ago Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update Xenetic Biosciences, Inc. reports financial results for Q1 2024 and progress on DNase-based oncology program, including ongoing preclinical studies and funds of $7.8 million Financial Results Xenetic Biosciences DNase-based Oncology Program Preclinical Studies Cash Reserves
BRIEF published on 03/22/2024 at 13:05, 2 years 5 months ago Xenetic Biosciences, Inc. présente ses performances financières et ses progrès en matière de développement pour l'année 2023 Résultats Financiers Produits Biopharmaceutiques Biosciences Xénétiques Programme D'oncologie Plateforme DNase
BRIEF published on 03/22/2024 at 13:05, 2 years 5 months ago Xenetic Biosciences, Inc. Presents Full Year 2023 Financial Performance and Development Progress Financial Results Xenetic Biosciences Biopharmaceuticals Oncology Program DNase Platform
PRESS RELEASE published on 03/22/2024 at 13:00, 2 years 5 months ago Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results Xenetic Biosciences reports financial results for 2023, highlighting progress on DNase-based oncology program leading to Phase 1 study for pancreatic carcinoma & solid tumors, ending year with $9.0 million Financial Results Xenetic Biosciences Solid Tumors DNase-based Oncology Program Pancreatic Carcinoma
Published on 09/17/2026 at 15:55, 1 hour 43 minutes ago Empress Announces Agreement to Acquire Tongon Gold Stream and Secures Debt Financing
Published on 09/17/2026 at 15:25, 2 hours 13 minutes ago AIAI Holdings' Constellation Network Launches Dôr Patient Journey with Proactive MD(R), Expanding Transformational AI In Healthcare
Published on 09/17/2026 at 15:00, 2 hours 38 minutes ago Norsemont Hits 41 Meters of 4.59 g/t Gold as Phase 3 Drilling Continues to Expand the Choquelimpie System
Published on 09/17/2026 at 15:00, 2 hours 38 minutes ago ECC Ventures 4 Announces Termination of Agreement With Cambria Gold Mines Inc.
Published on 09/17/2026 at 14:50, 2 hours 48 minutes ago Caldwell Strengthens Human Resources Practice with Addition of Ali Palmer as Partner
Published on 09/17/2026 at 17:15, 23 minutes ago Huawei Unveils the Industry's First NPO Optical Engine with Built-in Light Source, Hi-ONE, Leading the Way in High-Speed Optical Interconnect Technology Innovation
Published on 09/17/2026 at 17:00, 38 minutes ago Advancing the Agentic World, Building a Solid Silicon Foundation
Published on 09/17/2026 at 16:48, 49 minutes ago Elmos Semiconductor SE secures additional wafer capacity in Dortmund
Published on 09/17/2026 at 15:30, 2 hours 8 minutes ago Huawei Introduces OceanStor M900 Context Memory Storage to Accelerate AI Inference in Hyperscale Data Centers
Published on 09/17/2026 at 15:08, 2 hours 30 minutes ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
